P3 Health Partners Inc. (PIII): Submission of Matters to a Vote of Security Holders

P3 Health Partners Inc. (PIII) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. piii-20260609 0001832511 false 0001832511 2026-06-09 2026-06-09 0001832511 us-gaap:CommonClassAMember 2026-06-09 2026-06-09 0001832511 us-gaap:WarrantMember 2026-06-09 2026-06-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSU

Event · Shareholder vote
Original reporting
Published Jun 9, 2026, 9:54 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 10, 2026, 10:30 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$PIII
Neutral
medium confidence
Mentioned
$PIII
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$PIIINeutralLow
01

Why it matters

Proposals 2–4 were approved, including Nasdaq Rule 5635(d) approval to issue up to 3,341,130 Class A shares upon exercise of outstanding warrants held by VBC Growth SPV 5, LLC.

02

Market read

The only potentially tradable item is the approved warrant-related share issuance authorization, which can influence dilution/warrant overhang expectations.

03

What to watch

Traders may focus on whether warrant holders are likely to exercise soon versus later, which is not quantified in the filing.

Relevance 6/10Novelty 4/10Timing: after-hours/filing update from June 9, 2026 annual meeting results

Background

The SEC 8-K reports matters submitted to a vote at P3 Health Partners’ 2026 annual meeting on June 9, 2026.

Company-level read

Ticker impact

$PIIINeutralMedium confidence
Context

P3 Health Partners reported 2026 annual meeting voting results, including approval to issue up to 3,341,130 shares on warrant exercise.

Expected impact

Likely limited near-term impact; any move would be driven by how traders price potential dilution from warrant exercises.

Evidence & confidence

The filing is a corporate governance/authorization update (not a new financing or deal), but it explicitly approves a defined share issuance amount tied to warrants.

Market effects

Minimal; this is company-specific governance and warrant-share issuance mechanics.

None indicated.

None indicated.

Counterpoint

Even with approval, actual warrant exercise timing/likelihood may be low, so dilution may not materialize soon.

Key entities

  • P3 Health Partners Inc.

    Company filing the 8-K; held annual meeting and reported voting outcomes.

  • VBC Growth SPV 5, LLC

    Holds outstanding Class A common stock warrants whose exercise could trigger issuance of up to 3,341,130 shares.

  • BDO USA, P.C.

    Ratified as independent registered public accounting firm for fiscal year ending Dec. 31, 2026.

Related articles

$PIIIMed

P3 Health (PIII) Q3 2026 Earnings Call Transcript

P3 Health (PIII) reported Q3 2026 Adjusted EBITDA of $21M, raising full-year guidance to $90M-$100M. CEO Aric Coffman highlighted medical cost management, quality improvements, and growth strategies. The company is expanding in existing markets and entering new ones, like Nebraska, with a capital-efficient approach.

$PIIIMed

P3 Health Partners Announces Third Quarter 2026 Results

P3 Health Partners Inc. (PIII) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 P3 Health Partners Announces Third Quarter 2026 Results Adjusted EBITDA of $21 Million for the Third Quarter and $101 Million Year-to-Date Raises Full-Year 2026 Adjusted EBITDA Guidance Midpoint Management to Host Conference Call and Webcast November 9, 2026 at 4:30

$PIIIMedAI 9/10

P3 Health Partners (PIII) Q2 2026 Earnings Call Transcript

P3 Health Partners (PIII) reported Q2 2026 adjusted EBITDA of $54.4 million versus a prior-year loss, on total revenue of $386.4 million (+9% YoY). At-risk membership fell 10% to 105,000. Net income was $15.7 million. The company raised full-year 2026 guidance to adjusted EBITDA of $80 million to $110 million and revenue of $1.5 billion to $1.6 billion.